Opinion
Video
Panelists discuss how the Effisayil 2 trial's results suggest that spesolimab offers a promising strategy for reducing the frequency and severity of GPP flares, potentially revolutionizing the management of this severe and life-threatening condition.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.